ArticleFrontiers in medicine2025
Increased risk of deep vein thrombosis, pulmonary embolism, and all-cause mortality in chronic venous disorder: a large-scale retrospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic venous disorder (CVD), often overlooked as a significant medical burden, has recently been linked to severe health risks, especially deep vein thrombosis (DVT), and pulmonary embolism (PE). However, large-scale data are lacking. Specifically, the impact of CVD severity on the risk of thromboembolic events and the impact of procedural interventions on these risks are unknown. Methods: A retrospective cohort study of mortality and serious adverse events was conducted using electronic health records derived from the TriNetX database. Propensity-score matching and sensitivity analyses were performed to mitigate bias. Results: We included 463,313 patients with CVD. An increased risk of superficial vein thrombosis [SVT; hazard ratio (HR), 19.0, 95% confidence interval (CI) 17.1-21.0, Discussion: Independently of disease severity, CVD entails an increased risk for venous thromboembolic events and all-cause mortality. In CVD patients, procedural interventions are associated with reduced risks for DVT, PE and all-cause mortality. Confirmation of these potentially clinically relevant findings necessitates prospective randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.